Society guideline links: COVID-19 – General guidelines for management

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Management for specific patient populations, along with links to other COVID-19 related guidelines, are provided separately. (See "Society guideline links: COVID-19 – Index of guideline topics".)

International

●World Health Organization (WHO): Therapeutics and COVID-19 – Living guideline (2022)

●WHO: Living guidance for clinical management of COVID-19 (2021)

●Endocrine Society (ES): A statement on dexamethasone and COVID-19 (2020)

●WHO: Corticosteroids for COVID-19 – Living guidance (2020)

●WHO: Home care for patients with suspected or confirmed COVID-19 and management of their contacts – Interim guidance (2020)

●WHO: Use of chest imaging in COVID-19 – A rapid advice guide (2020)

Canada

●Public Health Agency of Canada (PHAC): National case definition – Coronavirus disease (COVID-19) (2023)

●PHAC: Considerations for the use of nirmatrelvir/ritonavir to treat COVID-19 in the context of limited supply (2022)

●PHAC: COVID-19 signs, symptoms, and severity of disease – A clinician guide (2022)

●Updated guidance on use and prioritization of monoclonal antibody therapy for treatment of COVID-19 in adolescents (2022)

●Canadian Society of Thoracic Radiology (CSTR) and Canadian Association of Radiologists (CAR): Statement on COVID-19 (2020)

●Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2 (2020)

United States

●National Institutes of Health (NIH): COVID-19 treatment guidelines

•Anti-SARS-CoV-2 antibody products

•Antiviral therapy

•Clinical management of adults

•Clinical management of children

•Clinical spectrum of SARS-CoV-2 infection

•Considerations for certain concomitant medications in patients with COVID-19

•Immunomodulators

•Overview of COVID-19

•Prioritization of anti-SARS-CoV-2 therapies for the treatment and prevention of COVID-19 when there are logistical or supply constraints

•Supplements

●Centers for Disease Control and Prevention (CDC): Clinical care considerations – Clinical considerations for care of children and adults with confirmed COVID-19 (2023)

●CDC: Underlying medical conditions associated with high risk for severe COVID-19 – Information for healthcare providers (2023)

●Infectious Diseases Society of America (IDSA): Guidelines on the treatment and management of patients with COVID-19 (2021, updated 2023)

●CDC: Clinical care quick reference for COVID-19 (2022)

●Updated guidance on use and prioritization of monoclonal antibody therapy for treatment of COVID-19 in adolescents (2022)

●American College of Radiology (ACR): Recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection (2020)

●American Thoracic Society (ATS)/European Respiratory Society (ERS): Updated guidance on the management of COVID-19 (2020)

●Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2 (2020)

Europe

●European Respiratory Society (ERS): Statement on long COVID-19 follow-up (2022)

●European Society of Clinical Microbiology and Infectious Diseases (ESCMID): COVID-19 living guidelines for drug treatment and clinical management (2022)

●ESCMID: Rapid guidelines for assessment and management of long COVID (2022)

●American Thoracic Society (ATS)/ERS: Updated guidance on the management of COVID-19 (2020)

●European Centre for Disease Prevention and Control (ECDC): Case definition for coronavirus disease 2019 (COVID-19) (2020)

●European Society for Paediatric Radiology (ESPR): Practical recommendations for management strategies for children with COVID-19 (2020)

United Kingdom

●National Institute for Health and Care Excellence (NICE): COVID-19 rapid guideline – Managing COVID-19 (2021, updated 2024)

●NICE: COVID-19 rapid guideline – Managing the long-term effects of COVID-19 (2020, updated 2024)

●Scottish Intercollegiate Guidelines Network (SIGN): Guideline on managing the long-term effects of COVID-19 (2021)

●UK Health Security Agency (UKHSA): Guidance on COVID-19 – Investigation and management of suspected SARS-CoV-2 reinfections (2021)

●British Society of Thoracic Imaging (BSTI): Thoracic imaging in COVID-19 infection – Guidance for the reporting radiologist (2020)

●Diabetes UK, Joint British Diabetes Societies (JBDS), and Association of British Clinical Diabetologists (ABCD): Concise advice on Inpatient Diabetes (COVID: Diabetes) – Dexamethasone/glucocorticosteroid therapy in COVID-19 patients: Implications and guidance for the management of blood glucose in people with and without diabetes (2020)

India

●All India Institute of Medical Science (AIIMS)/Indian Council of Medical Research (ICMR)/Government of India Ministry of Health & Family Welfare (MHFW): Clinical guidance for management of adult COVID-19 patients (2023)

●ICMR: Revised advisory on the use of hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection (2020)

Australia–New Zealand

●National COVID-19 Clinical Evidence Taskforce: Living guidelines on caring for people with COVID-19 (2023)

●New South Wales (NSW) Health: Care of adults and children in the community with COVID-19 – Standard clinical assessment and risk of deterioration assessment (2021, reviewed 2023)

●NSW Health: Guidance for the use of anti-SARS-CoV-2 monoclonal antibodies and antiviral agents as prophylaxis or to prevent severe infection from COVID-19 in NSW (2021, reviewed 2023)

●NSW Health: Clinical practice guide for assessment and management of adults with post-acute sequelae of COVID-19 (2022)

●NSW Health: Care of adult patients with COVID-19 in acute inpatient wards (2021)

●NSW Health: Management of adults with COVID-19 in the post-acute phase – A model of care for NSW health clinicians (2021)

Japan

●[In Japanese] Choosing Wisely Japan: Do not prescribe unproven therapeutic agents to COVID-19 patients except in approved clinical trials (2020)

●[In Japanese] Japan Pediatric Society (JPS), Japan Pediatric Infectious Diseases Society (JPIDS), Japan Outpatient Pediatric Society: Coronavirus infection 2019 (COVID-19) medical treatment guidelines in pediatric outpatient clinics (2020)

●[In Japanese] National Institute of Infectious Diseases (NIID): New coronavirus infectious disease, health and infection control at home treatment (2020)

Resources for patients — The following links provide resources about COVID-19 for non-clinicians. These resources come from select society and government-sponsored guidelines from several countries and regions around the world.

●[International] World Health Organization (WHO): Coronavirus disease (COVID-19) – Home care for families and caregivers

●[United States] Centers for Disease Control and Prevention (CDC): If you are sick or caring for someone

●[United Kingdom] National Health Service (NHS): How to look after yourself at home if you have coronavirus (COVID-19) or symptoms of COVID-19

●[United Kingdom] NHS: Long-term effects of coronavirus (long COVID)

UpToDate also offers "The Basics" patient education pieces, which are written by the doctors and editors at UpToDate. These are written in plain language, at the 5^th to 6^th grade reading level, and answer the main questions a person is likely to have. (See "Patient education: COVID-19 overview (The Basics)" and "Patient education: COVID-19 and children (The Basics)" and "Patient education: COVID-19 and pregnancy (The Basics)" and "Patient education: COVID-19 vaccines (The Basics)".)